Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fasudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 8/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 7/20 | 1.00 |
| ▸ | CCR2 | P41597 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.98 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.98 |
| ▸ | PRKD1 | Q15139 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.98 |
| ▸ | PRKCG | P05129 | 5/20 | 0.98 |
| ▸ | PRKCB | P05771 | 5/20 | 0.98 |
| ▸ | PRKCA | P17252 | 5/20 | 0.98 |
| ▸ | PRKCH | P24723 | 5/20 | 0.98 |
| ▸ | PRKCI | P41743 | 5/20 | 0.98 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.98 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.98 |
| ▸ | PRKACA | P17612 | 4/20 | 0.98 |
| ▸ | PRKACG | P22612 | 4/20 | 0.98 |
| ▸ | PRKACB | P22694 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fasudil SCHEMBL599053 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL29393852 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL30084458 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL317082 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL6032335 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL30064396 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL6269513 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL4728659 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL4725334 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL2154690 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600704-B2 | Substituted 1,2,4-triazoles and methods of use | STINGINN LLC (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260014253-A1 | CHECKPOINT REGULATOR ANTAGONISTS | GENSUN BIOPHARMA INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250361306-A1 | ANTITUMOR IMMUNE CHECKPOINT REGULATOR ANTAGONISTS | GENSUN BIOPHARMA INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4627061-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| EP-4627062-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| US-12410174-B1 | Small molecular inhibitors of sting signaling compositions and methods of use | TYERELL IMMUNOTHERAPEUTICS INC (US) | 2025-09-09 | — | — | US | disclosed |
| US-12404336-B2 | Bispecific antagonist comprising a LAG-3 binding domain | GENSUN BIOPHARMA, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-12378608-B2 | Methods for developing urine biomarkers and for detecting bladder cancer | EXOSOME DIAGNOSTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4075980-B1 | SUBSTITUTED 1,2, 4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12357608-B2 | Methods and compositions utilizing RRx-001 combination therapy for radioprotection | EPICENTRX, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3990116-A1 | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD | Gensun Biopharma Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114391015-A | Benzo [ b ] [1,8] naphthyridineacetic acid derivatives and methods of use | 斯汀塞拉股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114340735-A | Antitumor antagonist composed of mutated TGF beta 1-RII extracellular domain and immunoglobulin scaffold | 璟尚生物制药公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114302875-A | Oxoacridinylacetic acid derivatives and methods of use | 斯汀塞拉股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| WO-2022072601-A1 | ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES | NA BIOTECH CORP (US) | 2022-04-07 | — | — | WO | disclosed |
| EP-3969438-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | Stingthera, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3969452-A1 | BENZO[B][1,8]NAPHTHYRIDINE ACETIC ACID DERIVATIVES AND METHODS OF USE | Stingthera, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11273142-B2 | Treatment for tumors driven by metabolic dysfunction | SYNDEVRX, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| CN-111909088-B | Method for preparing isoquinoline hydrochloride intermediate and Rho kinase inhibitor by using BTC/Ph3PO chloro-system | 浙江工业大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-113968841-A | Preparation method of fasudil hydrochloride hemihydrate | 合肥久诺医药科技有限公司 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410174-B1 | Small molecular inhibitors of sting signaling compositions and methods of use | STING1, IRF3, MAVS | ROCK2 896/4885ROCK1 964/4885CCR2 2127/4885 |
| US-20260014253-A1 | CHECKPOINT REGULATOR ANTAGONISTS | PDCD1LG2, PDCD1, CD274 | ROCK2 3135/4885ROCK1 2475/4885CCR2 1286/4885 |
| US-12357608-B2 | Methods and compositions utilizing RRx-001 combination therapy for radioprotection | RBX1, RDX, PRDX1 | ROCK2 1808/4885ROCK1 1085/4885CCR2 4246/4885 |
| US-11273142-B2 | Treatment for tumors driven by metabolic dysfunction | PCK2, GOT2, PC | ROCK2 555/4885ROCK1 1578/4885CCR2 2751/4885 |
| US-12600704-B2 | Substituted 1,2,4-triazoles and methods of use | STING1, IRF3, MAVS | ROCK2 2918/4885ROCK1 2927/4885CCR2 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.